Compared to Estimates, Amgen (AMGN) Q1 Earnings: A Look at Key Metrics

Amgen (AMGN) reported $8.15 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 9.4%. EPS of $4.90 for the same period compares to $3.96 a year ago.The reported revenue represents a surprise of +2.47% over the Zacks Consensus Estimate of $7.95 billion. With the consensus EPS estimate being $4.16, the EPS surprise was +17.79%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- Neulasta- ROW: $20 million versus the seven-analyst average estimate of $26.10 million. The reported number represents a year-over-year change of -35.5%. Product Sales- Neulasta- U.S. $109 million versus the seven-analyst average estimate of $67.86 million. The reported number represents a year-over-year change of +25.3%. Product Sales- Otezla- ROW: $94 million compared to the $103.34 million average estimate based on six analysts. The reported number represents a change of -6.9% year over year. Product Sales- Otezla- U.S. $343 million compared to the $299.70 million average estimate based on six analysts. The reported number represents a change of +17.1% year over year. Product Sales- BLINCYTO- Total: $370 million compared to the $337.78 million average estimate based on 10 analysts. The reported number represents a change of +51.6% year over year. Product Sales- Repatha- Total: $656 million versus the 10-analyst average estimate of $615.59 million. The reported number represents a year-over-year change of +26.9%. Product Sales- KYPROLIS- Total: $324 million versus the 10-analyst average estimate of $381.49 million. The reported number represents a year-over-year change of -13.8%. Product Sales- Vectibix- Total: $267 million versus the 10-analyst average estimate of $250.50 million. The reported number represents a year-over-year change of +8.1%. Product Sales- Enbrel- Total: $510 million versus $502.53 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a -10.1% change. Revenue- Other revenues: $276 million versus the 10-analyst average estimate of $347.10 million. The reported number represents a year-over-year change of -16.1%. Product Sales- Neulasta- Total: $129 million compared to the $93.87 million average estimate based on 10 analysts. The reported number represents a change of +9.3% year over year. Revenue- Product sales: $7.87 billion compared to the $7.59 billion average estimate based on 10 analysts. The reported number represents a change of +10.6% year over year. View all Key Company Metrics for Amgen here>>>Shares of Amgen have returned -4.8% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks